1.BARACOS V E. Cancer-associated malnutrition[J]. Eur J Clin Nutr, 2018, 72(9):1255-1259.
2.CEDERHOLM T, BARAZZONI R, AUSTIN P, et al. ESPEN guidelines on definitions and terminology of clinical nutrition[J]. Clin Nutr, 2017, 36(1):49-64.
3.中国抗癌协会肿瘤营养与支持治疗专业委员会.肿瘤恶液质营养治疗指南[J/CD].肿瘤代谢与营养电子杂志, 2015, 2(3):27-31.
4.MORLEY J E, ANKER S D, VON HAEHLING S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014 [published correction appears in J Cachexia Sarcopenia Muscle, 2015 Jun;6(2):192][J]. J Cachexia Sarcopenia Muscle, 2014, 5(4):253-259.
5.VON HAEHLING S, ANKER M S, ANKER S D. Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016[J]. J Cachexia Sarcopenia Muscle, 2016, 7(5):507-509.
6.MUSCARITOLI M, ANKER S D, ARGILS J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”[J]. Clin Nutr, 2010, 29(2):154-159.
7.EVANS W J, MORLEY J E, ARGILS J, et al. Cachexia: a new definition[J]. Clin Nutr, 2008, 27(6):793-799.
8.SUN L, QUAN X Q, YU S. An Epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status[J]. Nutr Cancer, 2015, 67(7):1056-1062.
9.ARENDS J, BARACOS V, BERTZ H, et al. ESPEN expert group recommendations for action against cancer-related malnutrition[J]. Clin Nutr, 2017, 36(5):1187-1196.
10.HBUTERNE X, LEMARI E, MICHALLET M, et al. Prevalence of malnutrition and current use of nutrition support in patients with cancer[J]. JPEN J Parenter Enteral Nutr, 2014, 38(2):196-204.
11.BARACOS V E, MAZURAK V C, BHULLAR A S.CaIlcer cacbexia is defied by an ongoing loss of skeletal muscle mass[J].Ann Palliat Med.2019, 8 (1):3-12.
12.VON HAEHLING S, ANKER S D. Cachexia as major underestimated unmet medical need: facts and numbers[J]. Int J Cardiol, 2012, 161(3):121-123.
13.于恺英, 刘俐惠, 石汉平.肿瘤营养相关状况诊断标准[J/CD].肿瘤代谢与营养电子杂志, 2020, 7(1):1-4.
14.ROUBENOFF R. Molecular basis of inflammation: relationships between catabolic cytokines, hormones, energy balance, and muscle[J]. JPEN J Parenter Enteral Nutr, 2008, 32(6):630-632.
15.FEARON K, STRASSER F, ANKER S D, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol, 2011, 12(5):489-495.
16.DE MATOS-NETO E M, LIMA J D, DE PEREIRA W O, et al. Systemic inflammation in cachexia - is tumor cytokine expression profile the culprit? [J]. Front Immunol, 2015, 6:629.
17.沈霜婷, 郑喆文, 廖正凯.恶液质与肿瘤转移的相关分子机制[J/CD].肿瘤代谢与营养电子杂志, 2018, 5(2):134-138.
18.CARSON J A, BALTGALVIS KA. Interleukin 6 as a key regulator of muscle mass during cachexia[J]. Exerc Sport Sci Rev, 2010, 38(4):168-176.
19.INCIO PINTO N, CARNIER J, OYAMA L M, et al. Cancer as a proinflammatory environment: metastasis and cachexia[J]. Mediators Inflamm, 2015, 2015:791060.
20.HENDERSON S E, MAKHIJANI N, MACE T A. Pancreatic cancer-induced cachexia and relevant mouse models[J]. Pancreas, 2018, 47(8):937-945.
21.SHUKLA S K, MARKOV S D, ATTRI K S, et al. Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia[J]. Cancer Lett, 2020, 484:29-39.
22.HE W A, BERARDI E, CARDILLO V M, et al. NF-κB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia[J]. J Clin Invest, 2013, 123(11):4821-4835.
23.HARRIS W S, MILLER M, TIGHE A P, et al. omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives[J]. Atherosclerosis, 2008, 197(1):12-24.
24.LIU G, BIBUS D M, BODE A M, et al. Omega 3 but not omega 6 fatty acids inhibit AP-1 activity and cell transformation in JB6 cells[J]. Proc Natl Acad Sci U S A, 2001, 98(13):7510-7515.
25.BARBER MD, ROSS JA, VOSS AC, et al. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer[J]. Br J Cancer, 1999, 81(1):80-86.
26.HIGGINS J P, ALTMAN D G, GTZSCHE P C, et al. The Cochrane Collaborations tool for assessing risk of bias in randomised trials[J]. BMJ, 2011, 343: d5928.
27.JIANG H, SUN MW, HEFRIGHT B, et al. Efficacy of hypocaloric parenteral nutrition for surgical patients: a systematic review and meta-analysis[J]. Clin Nutr, 2011, 30(6):730-737.
28.HIGGINS J P, THOMPSON S G, DEEKS J J, et al. Measuring inconsistency in meta-analyses[J]. BMJ, 2003, 327(7414):557-560.
29.MACASKILL P, WALTER S D, IRWIG L. A comparison of methods to detect publication bias in meta-analysis[J]. Stat Med, 2001, 20(4):641-654.
30.BAUER J, CAPRA S, BATTISTUTTA D, et al. Cancer Cachexia Study Group. Compliance with nutrition prescription improves outcomes in patients with unresectable pancreatic cancer[J]. Clin Nutr, 2005, 24(6):998-1004.
31.KANAT O, CUBUKCU E, AVCI N, et al. Comparison of three different treatment modalities in the management of cancer cachexia[J]. Tumori, 2013, 99(2):229-233.
32.MANTOVANI G, MACCI A, MADEDDU C, et al. Randomized phase Ⅲ clinical trial of five different arms of treatment in 332 patients with cancer cachexia[J]. Oncologist, 2010, 15(2):200-211.
33.SOLHEIM T S, LAIRD B J A, BALSTAD T R, et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer[J]. J Cachexia Sarcopenia Muscle, 2017, 8(5):778-788.
34.SOLS-MARTNEZ O, PLASA-CARVALHO V, PHILLIPS-SIXTOS G, et al. Effect of eicosapentaenoic acid on body composition and inflammation markers in patients with head and neck squamous cell cancer from a public hospital in Mexico[J]. Nutr Cancer, 2018, 70(4):663-670.
35.JATOI A, ROWLAND K, LOPRINZI C L, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort[J]. J Clin Oncol, 2004, 22(12):2469-2476.
36.FEARON K C, BARBER M D, MOSES A G, et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia[J]. J Clin Oncol, 2006, 24(21):3401-3407.
37.AARONSON N K, AHMEDZAI S, BERGMAN B, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology[J]. J Natl Cancer Inst, 1993, 85(5):365-376.
38.HANAHAN D, WEINBERG R A. Hallmarks of cancer: the next generation, Cell, 2011, 144(5):646-674.
39.DIAKOS C I, CHARLES K A, MCMILLAN D C, et al. Cancer-related inflammation and treatment effectiveness[J]. Lancet Oncol, 2014, 15(11):e493-e503.
40.BARKER T, FULDE G, MOULTON B, et al. An elevated neutrophil-to-lymphocyte ratio associates with weight loss and cachexia in cancer[J]. Sci Rep, 2020, 10(1):7535.
41.KLASSEN P, CERVANTES M, MAZURAK V C. N-3 fatty acids during chemotherapy: toward a higher level of evidence for clinical application[J]. Curr Opin Clin Nutr Metab Care, 2020, 23(2):82-88.
42.COLOMER R, MORENO-NOGUEIRA J M, GARCA-LUNA P P, et al. N-3 fatty acids, cancer and cachexia: a systematic review of the literature[J]. Br J Nutr, 2007, 97(5):823-831.